Ozempic Hair Loss: What STEP and SUSTAIN Trial Data Actually Show

Reviewed by Dr. Sarah Mitchell, PhD, Biochemistry
Topics: GLP-1 Semaglutide Weight Loss
Ozempic Hair Loss: What STEP and SUSTAIN Trial Data Actually Show
⚠️ Research Disclaimer: This content is for educational purposes only. All compounds discussed are research peptides. Consult a qualified healthcare professional before considering any protocol.

Ozempic hair loss is one of the most-searched semaglutide side effects — but it is not a direct effect of the drug. In the Phase 3 STEP trials, hair-loss events were reported at ~3–5% on semaglutide vs ~1% on placebo. The mechanism is almost always telogen effluvium triggered by rapid weight loss, not a semaglutide-specific toxicity. This review walks through what the trial data actually show, why the shedding typically appears 2–4 months in, and whether it reverses.

Key Takeaways

  • Trial rates are modest. STEP-1 reported alopecia in ~3% of semaglutide 2.4 mg vs ~1% of placebo; STEP-5 (104 weeks) reported ~5%.
  • Mechanism is telogen effluvium. Rapid caloric deficit and weight loss shift hair follicles into the shedding phase — this is well-documented after bariatric surgery and crash diets, independent of GLP-1 drugs.
  • Timing is 2–4 months after rapid loss begins. This is the characteristic telogen effluvium lag; it is not an acute reaction.
  • Reversal is the norm. Shedding typically resolves within 3–6 months of weight stabilization, with full regrowth over 6–12 months.
  • Rate of weight loss matters more than drug choice. Faster titration + larger deficit = more shedding risk across any weight-loss method.
  • Nutritional support helps. Protein, iron, zinc, and biotin adequacy mitigate but do not eliminate the risk.

What the trials reported

Semaglutide Phase 3 programs tracked adverse events using MedDRA preferred terms, with "alopecia" the primary term for hair loss. Rates clustered consistently in the low single digits:

TrialSemaglutide armAlopecia rate (semaglutide)Alopecia rate (placebo)
STEP-12.4 mg weekly~3%~1%
STEP-2 (T2D)2.4 mg weekly~3%~1%
STEP-3 (behavior therapy)2.4 mg weekly~4%~1%
STEP-5 (104 weeks)2.4 mg weekly~5%~2%
SUSTAIN-1 to -10 (T2D doses)0.5 to 2.0 mg<1%<1%

Two patterns matter. First, hair loss rates on semaglutide T2D doses (SUSTAIN) are not meaningfully elevated versus placebo. The signal only appears clearly at the higher 2.4 mg obesity dose, which is also where weight loss is largest. Second, longer trials show modestly higher rates — consistent with cumulative telogen effluvium exposure over sustained weight loss.

Why rapid weight loss causes hair shedding

Telogen effluvium is a well-characterized condition in dermatology. Normal hair follicles cycle through anagen (growth, ~2–7 years), catagen (regression, ~2 weeks), and telogen (resting, ~3 months) phases. At any given time, ~85% of scalp hairs are in anagen and ~15% in telogen. Shedding occurs at the end of telogen.

Rapid weight loss shifts a larger-than-normal fraction of follicles synchronously into telogen. The mechanism involves caloric restriction, protein deficit, and the inflammatory and hormonal stress of significant body-composition change. Because telogen lasts about 3 months, the shedding appears 2–4 months after the trigger — not immediately.

Bariatric surgery literature documents this clearly: 30–50% of patients experience post-surgical hair loss, peaking at month 3–6. The rate on semaglutide at 3–5% is substantially lower, consistent with the slower weight-loss trajectory than surgery.

Is it the drug or the weight loss?

The STEP data cannot cleanly separate drug effect from weight-loss effect because the drug causes the weight loss. But two observations suggest the weight loss is the primary driver:

  • SUSTAIN (T2D) doses cause less weight loss and show no clear alopecia signal.
  • STEP-3 (semaglutide + intensive behavior therapy) shows slightly more alopecia than STEP-1, consistent with the slightly larger average weight loss.

There is no plausible direct mechanism by which semaglutide binds hair follicles. GLP-1 receptors are not meaningfully expressed in hair-follicle keratinocytes. The downstream effect of weight loss on the hair cycle is the operating mechanism.

Timing and course

Characteristic trajectory of GLP-1-associated hair shedding, drawn from case reports and the STEP program adverse-event tables:

PhaseTimingWhat patients report
TriggerWeeks 0–8Rapid appetite reduction, early weight loss begins
Latent phaseWeeks 8–16No hair changes yet; follicles entering telogen
Peak sheddingWeeks 16–28Noticeable increase in daily hair fall, thinning most apparent at crown and temples
StabilizationWeeks 28–40Shedding rate normalizes if weight has plateaued
RegrowthWeeks 40–80New anagen hairs replace shed ones; full density restored for most

Can you reduce the risk?

Several interventions have at least observational support in the bariatric and dieting literature:

  • Adequate protein intake (0.8–1.0 g/kg body weight) — insufficient protein during rapid weight loss worsens hair cycle disruption.
  • Iron sufficiency — ferritin below ~40 ng/mL is associated with worse telogen effluvium; supplementation if labs show low stores.
  • Zinc, biotin, and vitamin D sufficiency — correct any documented deficiencies; routine high-dose supplementation in sufficient patients has no clear benefit.
  • Slower titration — gentler weight-loss velocity reduces the simultaneous telogen shift.
  • Scalp massage and gentle hair care — supportive, limited evidence.

Minoxidil (topical) is sometimes recommended for telogen effluvium management but has mixed evidence in acute shedding events.

When to see a clinician

Most Ozempic hair loss resolves without specific treatment. A dermatology or primary-care review is warranted when:

  • Shedding persists past 6 months of weight stabilization.
  • Hair loss is patchy (rather than diffuse) — suggests alopecia areata or scarring alopecia instead.
  • There is scalp pain, itch, or visible inflammation.
  • Shedding is accompanied by fatigue, cold intolerance, or dry skin — rule out thyroid dysfunction.

Conclusion

Hair loss on Ozempic is uncommon (3–5% at the top obesity dose), delayed (2–4 months after rapid weight loss starts), and almost always reversible within a year of weight stabilization. The mechanism is telogen effluvium triggered by the pace of weight change, not a direct semaglutide effect — which is why T2D doses with slower weight loss don't produce a clear alopecia signal. Protein and micronutrient sufficiency reduce but do not eliminate risk. For most patients, waiting out the shedding is the right call; dropping the drug for hair loss alone is unusual once the mechanism is understood.

Frequently Asked Questions

How common is hair loss on Ozempic?

Approximately 3–5% of patients at the 2.4 mg weight-loss dose over 68–104 weeks of treatment, versus 1–2% on placebo in the same trials.

When does Ozempic hair loss start?

Typically 2–4 months after starting the drug, which coincides with the peak rate of weight loss. Shedding is not an acute reaction.

Does Ozempic hair loss grow back?

Yes, in nearly all cases. Full regrowth usually occurs over 6–12 months after weight stabilizes.

Should I stop Ozempic because of hair loss?

Rarely. The shedding is almost always self-limiting; stopping the drug does not immediately halt the current shedding wave because the follicles are already in telogen.

Does biotin help with Ozempic hair loss?

Only if you are deficient. Routine biotin supplementation in sufficient individuals has no documented benefit and can confuse thyroid lab results.

Is Ozempic hair loss the same as telogen effluvium?

Yes. The clinical pattern reported on Ozempic matches telogen effluvium — diffuse shedding 2–4 months after a trigger, self-limiting and reversible.


Primary sources:

Research disclaimer: This article is a research review for educational use only. It is not medical advice. Persistent, patchy, or inflamed hair loss should be evaluated by a dermatologist. Semaglutide is FDA-approved for specific indications; use outside the approved indication, dose, or route should be discussed with a qualified prescriber.

Sources & Further Reading

Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384:989–1002. Phase 3 RCT
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389:2221–2232. Phase 3 RCT